Twist Bioscience Corporation
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M | $132.3M | $90.1M | $54.4M | $25.4M |
| Cost of Revenue | $185.6M | $179.6M | $155.4M | $119.3M | $80.6M | $61.4M | $47.4M | $32.2M |
| Gross Profit | $191.0M | $133.3M | $89.7M | $84.2M | $51.7M | $28.7M | $7.0M | $-6.8M |
| Gross Margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | 31.8% | 12.8% | -26.6% |
| Operating Expenses | ||||||||
| Research & Development | $80.3M | $90.9M | $106.9M | $120.3M | $69.1M | $43.0M | $35.7M | $20.3M |
| SG&A Expense | $247.0M | $218.4M | $189.7M | $212.9M | $135.9M | $103.3M | $80.1M | $43.5M |
| Operating Income | $-136.3M | $-220.8M | $-217.2M | $-234.8M | $-152.7M | $-140.1M | $-108.9M | $-70.6M |
| Operating Margin | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | -155.5% | -200.1% | -277.5% |
| Interest Expense | — | — | $5.0K | $80.0K | $367.0K | $787.0K | $1.3M | $1.3M |
| Pretax Income | $-77.0M | $-208.2M | $-203.5M | $-228.3M | $-154.0M | $-139.5M | $-107.4M | $-71.0M |
| Income Tax Expense | $719.0K | $560.0K | $1.2M | $-10.4M | $-1.9M | $382.0K | $292.0K | $242.0K |
| Net Income | $-77.7M | $-208.7M | $-204.6M | $-217.9M | $-152.1M | $-139.9M | $-107.7M | $-71.2M |
| Net Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | -155.3% | -198.0% | -280.2% |
| EPS (Basic) | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 | $-3.92 | $-25.51 |
| EPS (Diluted) | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 | $-3.57 | $-3.92 | $-25.51 |
| Shares Outstanding (Basic) | 59.8M | 58.0M | 56.9M | 53.9M | 48.3M | 39.2M | 33.1M | 3.2M |
| Shares Outstanding (Diluted) | 59.8M | 58.0M | 56.9M | 53.9M | 48.3M | 39.2M | 33.1M | 3.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |